A cell-free system for 1,6-hexanediamine synthesis using bulk chemical caprolactam as the feedstock Authors: Ren Liu, Chouqiang Li, Yihui Zhang, Guohui Li, Yu Deng Published: 2026 ABSTRACT Biomanufacturing, with its advantages of mildness, low carbon emissions, and renewability, drives the frontier of green chemistry and sustainable development. However, complex metabolic pathways and intracellular resource competition frequently limit the efficiency and yield of metabolic engineering approaches, particularly for non-natural compounds such as 1,6-hexanediamine (1,6-HMD), an important precursor for nylon 66. To address these challenges, we developed a cell-free biocatalytic system employing 6-aminocaproic acid (6-ACA), derived from low-cost caprolactam, together with optimized enzyme assembly and cofactor regeneration. As a result, the 1,6-hexanediamine titer was enhanced by 511-fold, reaching a record-high level of 10.35 g/L with a conversion rate of 97.4%. The system was further extended to the production of C7–C10 α,ω-diamines, achieving high-level titers. In addition, the cell-free biocatalytic system retained considerable activity after 7 days of storage at 4 °C, with a 25.9% reduction in titer. This cell-free biocatalysis overcame the inherent limitations of biological systems and preserved enzyme activity, demonstrating the substantial potential for efficient diamine synthesis and indicating broad applicability for future practical implementations. Introduction Biomanufacturing is at the forefront of the revolution in green chemistry and sustainable development [1,2]. It is widely applied in pharmaceuticals, chemicals, food, energy, materials, and agriculture [3,4]. Biocatalysis, one of the core technologies in this field, uses enzymes or microbial cells to drive chemical reactions, showcasing significant advantages in green chemistry [5,6]. However, traditional biocatalysis relies on living cells or microorganisms, which require substantial resources for chemical synthesis [7]. Furthermore, the metabolic pathways are complex and cell growth may be hindered by product toxicity and competition for resources often limits efficiency and yields [8]. Thus, overcoming the limitations inherent in living organisms and addressing the complexities of metabolic pathways and resource competition in microbial fermentation represent major challenges for biocatalysis. Aliphatic diamines are critical monomers in nylon production and are widely used in the manufacturing of polyamide plastics, including engineering plastics, fibers, films, and other applications [9,10]. In particular, Nylon 6 and Nylon 66 play a dominant role in the global nylon market, together accounting for 90% of the market share [11]. Among them, Nylon 66 reached a market value of $16.29 billion in 2019, and is projected to grow at an annual rate of 6.5% from 2019 to 2027, indicating strong market demand [12]. The industrial production of 1,6-hexanediamine (1,6-HMD), one of the key monomers for Nylon 66, primarily relies on adiponitrile hydrogenation with hydrogen cyanide [13,14]. However, its high toxicity imposes stringent equipment requirements, creating technical barriers. Therefore, the development of sustainable and environmentally friendly biotechnological processes for 1,6-HMD production has become a critical issue. Recently, Fedorchuk et al. developed a one-pot enzyme-cascade reaction system using adipic acid as the substrate, employing carboxylic acid reductase (CAR) and transaminase (TA) to synthesize 1,6-HMD from adipic acid [11]. Building upon this work, Wang et al. constructed an artificial pathway in E. coli for 1,6-HMD synthesis, which used a whole-cell biocatalytic system with CARs and TAs and successfully produced 238.5 mg/L of 1,6-HMD [15]. Zhang et al. also reported a cascade using cyclohexanol, yielding up to 16.5 mM [16]. Despite the potential of current methods for the production of 1,6-HMD, the yields are still relatively low and remain a major limitation. Because 1,6-HMD is a non-native compound, and E. coli lacks transport systems to accumulate it. Additionally, the accumulation of the intermediate 6-aminohexanal is toxic, impairing cell growth and enzyme activity [15,17]. In contrast, in vitro enzyme catalysis is somewhat superior to in vivo synthesis because it bypasses the metabolic burden of the cell and can enhance yield without the formation of side products. Shi et al. reported up to 16% conversion from 6-ACA using an in vitro cascade [18]. However, pure enzyme preparations are usually required, complicating operation and raising costs. Therefore, overcoming the inherent limitations of biological systems and preserving enzyme activity are crucial for improving 1,6-HMD yield. A cell-free system, either in the form of cell-free gene expression (CFGE) systems relying on coupled transcription-translation machinery, or cell-free lysates containing overproduced enzymes applied directly as crude extracts, is emerging as a promising alternative to traditional metabolic engineering, appreciated for its robustness and scalability, and capable of integrating multiple enzymes and cofactors to enable complex biotransformation [19,20]. Compared to conventional metabolic engineering, cell-free synthesis offers numerous advantages such as eliminating host constraints, modular pathway integration, tolerance to toxic intermediates, and improved yields, while allowing precise control of reaction conditions and flexible adjustment of enzyme and substrate concentrations. Nevertheless, challenges remain, including cofactor regeneration, enzyme instability, and scale up difficulties [[21], [22], [23]]. Despite these challenges, cell-free systems have enabled successful synthesis of complex compounds. For example, Dudley et al. used a cell-free system to synthesize mevalonic acid at high yield, avoiding toxic HMG-CoA accumulation [24]. In another study, Li et al. employed a cell-free system to achieve complete in vitro synthesis of valinomycin without transport proteins [25]. Given their success in synthesizing the above compounds, such systems could also be effective for producing 1,6-HMD. Caprolactam (CPL), the primary industrial precursor for nylon-6, can be efficiently hydrolyzed to yield 6-aminocaproic acid (6-ACA) via enzymatic or acidic catalysis [26,27]. In China, CPL is produced on a massive scale, with industrial capacity reaching several million tonnes annually and projected to exceed 8 million tonnes by 2028. This extensive production not only ensures a stable and abundant supply of CPL but has also driven down its market price due to capacity expansion and supply-demand imbalances. Consequently, 6-ACA derived from CPL represents a low-cost, readily accessible substrate, making it an attractive feedstock for biocatalytic processes. Given the availability and economic advantages of 6-ACA, we developed an efficient synthetic route for 1,6-HMD production using 6-ACA derived from CPL. To address challenges with product transport and the toxicity of 6-aminohexanal, different catalytic systems were evaluated, and the cell-free system was ultimately found to enhance 1,6-HMD production by bypassing these limitations. Meanwhile, the adopted system, with excellent stability at 4 °C, was versatile for C7–C10 α,ω-diamines synthesis, providing a sustainable route. Materials and methods Strains, plasmids, and genes The genes encoding MAB CARL342E from Mycobacteroides abscessus (GenBank ID: WP_005082584.1), SFP from Bacillus subtilis (GenBank ID: X63158), SPTA from Silicibacter pomeroyi (GenBank ID: WP_011049154), CVTA from Chromobacterium violaceum (GenBank ID: 6S4G_D), HATA from Hafnia alvei (GenBank ID: SCM51866), VFTA from Vibrio fluvialis (GenBank ID: 5ZTX_A), PatA from E. coli (GenBank ID: NP_417544), STTA from Solanum tuberosum (GenBank ID: XP_006351980), PDTA from Paracoccus denitrificans (GenBank ID: WP_011747074), BmGDH from Bacillus megaterium (GenBank ID: AAA22475) and PPK12 from an unclassified Erysipelotrichaceae bacterium (UniProt: A0A3D5XRJ5) were maintained in our laboratory. The smta gene encoding SMTA from Shimia marina (UniProt: A0A0P1EM06) was selected from the BRENDA enzyme database. All strains, plasmids, genes, and primers used in this study are listed in Table S1. Medium, cultivation and protein expression For protein expression, E. coli cells were initially activated on LB agar plates containing the appropriate antibiotics and incubated at 37 °C. A single colony was then transferred to 20 mL of LB liquid medium with antibiotics in a 100 mL shake flask and incubated at 37 °C with shaking at 250 rpm until the culture became turbid. The culture was then inoculated at a final volume corresponding to 2% inoculum (v/v) into 100 mL of LB medium containing antibiotics and 2 g/L glucose, in a 250 mL shake flask. The flask was incubated until the optical density (OD) at 600 nm reached 0.6, at which point induction was initiated. IPTG was subsequently added to a final concentration of 0.6 mM to induce protein expression, and the culture was incubated at 30 °C for 12 h. Biotransformation in whole-cell catalysis system 6-ACA was obtained from CPL via acid-catalyzed hydrolysis, and serves as the substrate for subsequent biocatalytic conversion to 1,6-HMD [28]. The whole-cell catalysis reaction mixture (4 mL) contained 10 mM MgCl2, 0.1 mM DTT, 1 mM PLP, 100 mM NADPH, 100 mM ATP, 50 mM glutamate, 50 mM alanine, 50 mM aspartate, 12 g/L 6-ACA, and catalyst loading (final cell wet weight 88 g/L). In this process, cells were permeabilized using one of the following treatments: 3% ethanol, 1% isopropanol (IPA), or 0.07% hexadecyltrimethylammonium bromide (CTAB). All components were dissolved in Tris-HCl buffer, with the pH adjusted to 7.5. The reaction was carried out in 24-well plates at 30 °C with shaking at 250 rpm for 12 h. Biotransformation in cell-free catalysis system After protein expression, the cells were washed with Tris-HCl buffer (100 mM, pH 7.5) and concentrated to a final OD600 of 150. The cells were then disrupted using a high-pressure homogenizer at 600-700 MPa for 6 min. The lysate was centrifuged to remove insoluble material, and the supernatant was collected as the cell-free catalyst for further use. The cell-free catalysis reaction mixture, with a total volume of 4 mL, consisted of 10 mM MgCl2, 0.1 mM DTT, 1 mM PLP, 10 mM ATP, 1.5 mM NADP+, 100 mM polyphosphate (polyP6), 100 mM glucose, 50 mM glutamate, 50 mM alanine, 50 mM aspartate, 12 g/L 6-ACA, 600 μg/mL PPK12 (purified, soluble enzyme), 1.2 mg/mL BmGDH and 50% cell-free catalyst (containing 6.5 mg/mL CAR and 3 mg/mL HATA). All components were dissolved in Tris-HCl buffer, with the pH adjusted to 7.5. The reaction was carried out at 30 °C with shaking at 250 rpm. Construction of cofactor regeneration systems To sustain cofactor availability in the cell-free system, coupled regeneration modules for both ATP and NADPH were constructed. ATP regeneration was achieved using a polyphosphate kinase together with hexameric polyphosphate (polyP6), where PPK12 from an unclassified Erysipelotrichaceae bacterium sequentially phosphorylates AMP to ADP and further to ATP [29]. For NADPH regeneration system, BmGDH from Bacillus megaterium was employed to continuously recycle NADP + to NADPH [30]. All enzymes were expressed in E. coli BL21(DE3) and purified for use in the cell-free system. Sample derivatization and analysis α,ω-Diamines were derivatized with dansyl chloride prior to analysis [15]. The derivatized samples were quantified by HPLC and qualitatively identified by LC-MS. Detailed derivatization and instrumental parameters are provided in the Supporting Information. Statistical analysis Results presented are mean ± standard error of the mean (SEM) from at least three independent determinations. The independent sample t-test method (SPSS) was employed to determine significant differences. ∗, P < 0.05, ∗∗, P < 0.01, ∗∗∗, P < 0.001. Results and discussion Construction of artificial 1,6-HMD pathways starting from 6-ACA E. coli BL21(DE3) is a commonly used host because of its fast growth rate, high transformation efficiency, and mature genetic operating system [31,32]. First, the test showed that E. coli BL21(DE3) had good tolerance to the product 1,6-HMD and the substrate 6-ACA, which met the requirements of pathway construction (Fig. S1). Therefore, an artificial pathway for 1,6-HMD was constructed using carboxylic acid reductase MAB CARL342E and transaminase SPTA, with 6-ACA, obtainable via hydrolysis of CPL (Fig. 1A). The genes encoding SPTA, MAB CARL342E, and SFP were heterologously expressed in E. coli, generating the 1,6-HMD engineering strain HMD1. The results showed that the strain HMD1 accumulated 20.2 mg/L 1,6-HMD with 8 g/L 6-ACA substrate under shaking flask conditions (Fig. 1B), and the LC-MS and HPLC spectrums of 1,6-HMD were shown in Fig. 1D and Fig. S2, which indicated that the biosynthesis pathway of 1,6-HMD was successfully constructed in E. coli.Fig. 1Construction of the 1,6-HMD synthesis pathway. (A) Conversion of 6-ACA to 1,6-HMD by CAR and TA. CAR, carboxylic acid reductase; TA, transaminase; (B) Synthesis of 1,6-HMD in strain HMD1. (C) Production of 1,6-HMD in whole-cell catalysis system with different permeability treatment. (D) LC−MS spectrum of derivatized 1,6-HMD. Construction of the 1,6-HMD synthesis pathway. (A) Conversion of 6-ACA to 1,6-HMD by CAR and TA. CAR, carboxylic acid reductase; TA, transaminase; (B) Synthesis of 1,6-HMD in strain HMD1. (C) Production of 1,6-HMD in whole-cell catalysis system with different permeability treatment. (D) LC−MS spectrum of derivatized 1,6-HMD. Studies have shown that whole-cell catalysis typically offers higher conversion rates compared to traditional fermentation, as it directly utilizes the intracellular enzyme system for catalysis [33,34]. To enhance the production of 1,6-HMD, a whole-cell catalytic system was developed based on an artificial biosynthetic pathway. The results demonstrated that the production of 1,6-HMD reached 101.9 mg/L, which was 5.0 times higher than that achieved by shake flask fermentation (Fig. 1C). The maximum production in fermentation was obtained after 96 h, while the whole-cell catalysis system achieved its peak titer in just 12 h, indicating a significantly shorter catalytic cycle and higher catalytic efficiency. However, as cells do not naturally synthesize 1,6-HMD, the lack of specific transport proteins and associated cellular components in vivo, limits the efficient transport of 1,6-HMD out cells, thus constraining its production [15]. Previous studies have reported that surfactants can enhance cell membrane permeability and facilitate substrate and product transport, thereby increasing 1,6-HMD production [35]. In this study, ethanol, IPA and CTAB were tested to enhance membrane permeability. The results indicated that the addition of 0.07% CTAB significantly enhanced 1,6-HMD titer, reaching 583.0 mg/L, which represents a 4.7-fold increase compared to the control and a 27.9-fold increase over shake flask fermentation (Fig. 1C). These findings suggest that using CTAB to permeabilize cells is an effective strategy for boosting 1,6-HMD production in a whole-cell catalysis system [36]. However, despite the significant production increase, the conversion rate remained only 5.5%, indicating that further optimization of cell permeability is needed to improve the transport efficiency of substrates and products. Design of a cell-free platform for the synthesis of 1,6-HMD To further relieve the restriction of cell membrane, a cell-free catalysis system was explored, where cells were disrupted, and the supernatant was used for catalysis (Fig. 2A). Three different expression systems—dual plasmid, tandem, and dual-cell systems—were evaluated for cell-free catalysis of 1,6-HMD (Fig. 2B). The results demonstrated that the cell-free catalysis consistently outperformed whole-cell catalysis, achieving at least a 3.5-fold increase in 1,6-HMD titer. This improvement is likely due to the ability of enzymes to function under optimal reaction conditions in the cell-free system, allowing for precise control of stoichiometry and overcoming the metabolic limitations inherent in live cells [37,38]. Among the three systems, both the dual-plasmid and tandem systems showed relatively low titers, with the dual-plasmid system producing only 2.6 g/L. This result may be attributed to plasmid competition or imbalance in expression, leading to uneven resource allocation within the cells and insufficient coordination of metabolic pathways, thereby limiting the improvement of overall catalytic efficiency [8]. In contrast, the dual-cell system exhibited the best catalytic performance, with a titer of 3.6 g/L, 5.2 times higher than whole-cell catalysis, significantly outperforming the other two systems. This substantial improvement is likely due to the division of metabolic functions between the two cell types, which reduces the metabolic burden on each individual cell and allows for more efficient resource allocation (Fig. 2A).Fig. 2The cell-free synthetic system for 1,6-HMD production (A) Flowchart of the cell-free catalytic system. (B) Production of 1,6-HMD under different expression patterns in cell-free catalysis system. The cell-free synthetic system for 1,6-HMD production (A) Flowchart of the cell-free catalytic system. (B) Production of 1,6-HMD under different expression patterns in cell-free catalysis system. Screening of improved transaminases in the cell-free system The carboxylic acid reductase MAB CARL342E has been reported to exhibit high catalytic activity towards the substrate 6-ACA, suggesting that the transaminase module may be the key factor limiting production [11]. Accordingly, seven representative transaminases were selected for systematic screening to address this limitation. Each of these enzymes was successfully expressed and purified (Fig. 3A). The performance of various transaminases in 1,6-HMD synthesis was assessed, revealing considerable differences in catalytic efficiency (Fig. 3B). Among the transaminases tested, the cell-free system using HATA exhibited the highest performance, achieving a titer of 8.0 g/L, 2.2 times higher than that of SPTA. By comparison, other transaminases adopted in the cell-free system, including CVTA, PatA, STTA, SMTA, VFTA, and PDTA, showed significantly lower 1,6-HMD titers at the same protein loading, with none proving suitable for efficient 1,6-HMD production. Kinetic characterization of SPTA and HATA revealed that HATA exhibited a 1.6-fold higher catalytic efficiency (kcat/Km = 0.34 × 103 M−1s−1) than SPTA (kcat/Km = 0.21 × 103 M−1s−1), primarily attributable to its stronger substrate affinity (Table S2). Collectively, these findings demonstrate that HATA is the most effective transaminase for 1,6-HMD biosynthesis. The higher titer of 1,6-HMD with HATA can be attributed to its specific suitability for substrates like 6-aminohexanal. As a diamine transaminase, HATA has a better catalytic profile for amination reactions involving medium-chain amines [[39], [40], [41]].Fig. 3Effect of transaminases on 1,6-HMD Synthesis. (A) Protein gel electrophoresis of purified transaminases. (B) Production of 1,6-HMD using different transaminases. ND, not detected. Effect of transaminases on 1,6-HMD Synthesis. (A) Protein gel electrophoresis of purified transaminases. (B) Production of 1,6-HMD using different transaminases. ND, not detected. Optimization and performance evaluation of the cell-free system for 1,6-HMD production Beyond enzyme selection, cofactor availability critically affects the efficiency of the cell-free system [42]. Carboxylic acid reductase requires NADPH and ATP as essential cofactors for catalytic conversion [43]. To reduce production costs and improve the economic feasibility of the process, NADPH and ATP regeneration systems were introduced to enable efficient cofactor recycling [44]. The total turnover numbers (TTNs) of the cofactor regeneration enzymes were estimated to be 4300 for PPK12 and 1700 for BmGDH, both well exceeding the threshold value of 1000, highlighting the economic viability of the regeneration systems for applications [45,46]. As a result, the production of 1,6-HMD reached 10.35 g/L after 10 h of reaction, corresponding to a substrate conversion rate of 97.4% (Fig. 4A). This represents a 511.4-fold and 16.8-fold enhancement compared to shake flask fermentation and whole-cell catalysis.Fig. 4Optimization and evaluation of cell-free system. (A) Optimization of catalysis time in the glucose-supplemented system. (B) Evaluation of crude enzyme stability under different temperature. Optimization and evaluation of cell-free system. (A) Optimization of catalysis time in the glucose-supplemented system. (B) Evaluation of crude enzyme stability under different temperature. In the study of the conversion of 6-ACA to 1,6-HMD, Fedorchuk et al. first engineered the CAR enzyme, obtaining the mutant CARL342E, which significantly enhanced its activity for 6-ACA. To better adapt CARL342E with transaminases, they had to use the coupled transaminases PatA and SAV2585, enabling the efficient conversion of 6-ACA to 1,6-HMD with a a conversion rate of 75.0% [11] (Fig. 5A). Later, Shi et al. further optimized CAR through enzyme redesign, obtaining the mutant CAR3 with higher conversion efficiency. This mutant, in combination with the transaminase SPTA, catalyzed the conversion of 6-ACA to 1,6-HMD at a concentration of 9.58 g/L with a conversion rate of 82.5% in a pure enzyme system [47] (Fig. 5B). However, the use of pure enzymes significantly increased production costs, which limits its broader applicability. In contrast, utilizing the CARL342E mutant and performing transaminase adaption assembly in a cell-free catalytic system, we significantly improved the compatibility and achieved the highest 1,6-HMD titer of 10.35 g/L (see Table 1), demonstrating the high efficiency of cell-free production (Table S3) [48]. Standardized performance metrics indicate that the crude enzyme-based cell-free system performs comparably to reported pure enzyme cascades (Table S4). Notably, the system employs crude enzymes rather than purified enzymes, reducing catalyst costs, and achieves the highest 1,6-HMD titer among the compared studies, demonstrating its potential for applications.Fig. 5Biocatalytic 1,6-HMD synthesis from 6-ACA. (A) Modification of MAB CAR to achieve biosynthesis of 1,6-HMD by pure enzyme catalysis. (B) Modification of MAB CARL342E for 1,6-HMD production using in vitro catalysis. (C) TAs adaptation and system optimization for 1,6-HMD production using cell-free system.Table 1Comparison of 1,6-HMD titers via biocatalytic synthesis.Table 1SubstrateCatalystTiters (g/L)Referencel-lysineMicrobial fermentation0.21[54]AAMicrobial fermentation0.24[15]cyclohexanolWhole-cell biocatalysis0.49[55]CHOLWhole-cell biocatalysis1.92[16]6-ACAPure enzyme catalysis0.09[56]6-ACAPure enzyme catalysis0.87[11]6-ACAPure enzyme catalysis2.01[18]6-ACAPure enzyme catalysis9.58[47]6-ACACell-free catalysis10.35This Study Biocatalytic 1,6-HMD synthesis from 6-ACA. (A) Modification of MAB CAR to achieve biosynthesis of 1,6-HMD by pure enzyme catalysis. (B) Modification of MAB CARL342E for 1,6-HMD production using in vitro catalysis. (C) TAs adaptation and system optimization for 1,6-HMD production using cell-free system. Table 1Comparison of 1,6-HMD titers via biocatalytic synthesis.Table 1SubstrateCatalystTiters (g/L)Referencel-lysineMicrobial fermentation0.21[54]AAMicrobial fermentation0.24[15]cyclohexanolWhole-cell biocatalysis0.49[55]CHOLWhole-cell biocatalysis1.92[16]6-ACAPure enzyme catalysis0.09[56]6-ACAPure enzyme catalysis0.87[11]6-ACAPure enzyme catalysis2.01[18]6-ACAPure enzyme catalysis9.58[47]6-ACACell-free catalysis10.35This Study Comparison of 1,6-HMD titers via biocatalytic synthesis. The stability of the crude enzyme solution was also assessed by storing the enzymes prepared at different temperatures (−80 °C, −20 °C, and 4 °C) for 7 d. The results showed that storage at −80 °C led to a 3.7% decrease in 1,6-HMD production, while storage at −20 °C and 4 °C resulted in 21.2% and 25.9% titer reduction respectively (Fig. 4B). These results suggest that crude enzymes exhibited acceptable stability under relatively mild storage conditions (4 °C). Therefore, storage at 4 °C could eliminate the high energy costs associated with ultra-low temperatures, simplifying the handling processes, and offering a more efficient long-term preservation solution for 1,6-HMD production. Together, these results, combined with the efficient NADPH generation from glucose, underscore the robustness and practicality of the system for 1,6-HMD production. The combination of stable enzyme activity and effective NADPH supplementation offers a promising strategy to reduce production costs while enhancing the overall efficiency. This integrated approach could significantly improve the economic feasibility and scalability of 1,6-HMD production. Furthermore, 1,6-HMD was isolated and purified from the reaction mixture via a desalting-extraction-rectification procedure (Fig. S3), achieving a purity of 97.2%. Application of cell-free system in the production of medium-chain α,ω-diamines A cell-free catalytic system has been successfully developed to efficiently convert 6-ACA into 1,6-HMD, with the selected transaminase HATA exhibiting excellent catalytic performance. Building on this, the system was further applied to the production of medium-chain α,ω-diamines to explore its catalytic potential. The results indicated that ω-amino fatty acids with carbon chain lengths ranging from C7 to C10 were efficiently converted with high titers. Specifically, the titers of C7–C10 diamines reached 10.58, 6.45, 2.17 and 5.09 g/L, with yields of 81.4%, 44.8%, 58.7% and 29.6%, respectively (Fig. 6). Notably, 9-aminononanoic acid (C9) and 10-aminocapric acid (C10) show very low aqueous solubility. As a result, these substrates were introduced into the reaction system in the solid state. As the reaction proceeded, the solid substrates gradually dissolved, and the reaction mixture became progressively clear. The products were confirmed by LC-MS analysis (Fig. S4). These results suggested that HATA was suitable for catalyzing the synthesis of medium-chain ω-amino fatty aldehydes, which exhibited higher catalytic efficiency for C6 substrates, likely due to its smaller molecular structure and tighter binding [49,50]. For longer-chain substrates, the reduced catalytic efficiency may be attributed to both the spatial constraints of the HATA active site and the odd-even carbon chain effect, which collectively influence substrate binding and turnover [[51], [52], [53]].Fig. 6Synthesis of medium-chain α,ω-diamines from ω-amino fatty acids in cell-free system. Synthesis of medium-chain α,ω-diamines from ω-amino fatty acids in cell-free system. The cell-free system demonstrated high catalytic efficiency in the production of medium-chain α,ω-diamines, showcasing its exceptional performance and significant potential. This achievement highlights the broad applicability of the system for the synthesis of medium-chain diamines and establishes a solid foundation for the cell-free catalysis of diamines. Conclusions In conclusion, we have developed an efficient cell-free biocatalytic method for the high-yield production of 1,6-HMD. Using 6-ACA derived from the low-cost and overproduced industrial feedstock CPL as the substrate, we achieved a record-high titer of 10.35 g/L with a yield of 97.4%, through enzyme component adaptation and cofactor strategies optimization. Furthermore, this system was successfully applied to produce α,ω-diamines, achieving high-level titers, with notable conversion rates for 1,7-heptanediamine, 1,8-octanediamine, 1,9-nonanediamine, and 1,10-decanediamine. These results demonstrate the significant potential of this cell-free biocatalysis system for the efficient synthesis of medium-chain diamines and other chemicals. CRediT authorship contribution statement Ren Liu: Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Chouqiang Li: Writing – review & editing, Visualization, Validation, Supervision, Project administration, Methodology, Formal analysis, Data curation, Conceptualization. Yihui Zhang: Investigation, Formal analysis, Data curation. Guohui Li: Writing – review & editing, Validation, Supervision, Resources, Project administration, Methodology, Funding acquisition, Formal analysis, Data curation, Conceptualization. Yu Deng: Supervision, Resources, Project administration, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.